Prostaglandin glycerol esters (PG-G) and prostaglandin ethanolamides (PG-EA) are generated by the action of cyclooxygenase-2 (COX-2) on the endocannabinoids, 2-arachidonylglycerol (2-AG) and arachidonylethanolamide (AEA), respectively. These novel eicosanoids may have unique pharmacological properties and/or serve as latent sources of prostaglandins at sites remote from their tissue of origin. Therefore, we investigated the metabolism of PG-Gs and PG-EAs in vitro and in vivo. PGE 2 -G was rapidly hydrolyzed in rat plasma to generate PGE 2 (t 1/2 = 14 s) but was only slowly metabolized in human plasma (t 1/2 » 10 min). An intermediate extent of metabolism of PGE 2 -G was observed in human whole blood (t 1/2 ≈ 7 min).
Introduction
Prostaglandins (PGs) are a class of unsaturated fatty acid metabolites with remarkably diverse and potent biological activities. Cyclooxygenases (COXs) catalyze the committed step in PG biosynthesis by oxygenating arachidonic acid to generate the hydroxy-endoperoxide, PGH 2 (1) . Subsequent cell-type specific metabolism of PGH 2 results in the production of the primary prostaglandins (E 2 , D 2 , F 2α ), prostacyclin, and thromboxane A 2 . PGs generated by COX action on arachidonic acid function as autocrine and paracrine messengers. Rapid PG catabolism in vivo prevents significant endocrine activity (2, 3) . For PGs present within the circulation, the initial step in metabolism is oxidation of the 15-hydroxyl group, which is catalyzed by 15- hydroxyprostaglandin dehydrogenase (15-HPGDH, EC 1.1.1.141) (4) (Eq. 1). The 15-keto derivatives that are produced exhibit dramatically reduced biological activity so their formation is considered to represent metabolic inactivation (5) (6) (7) (8) .
Insert eq 1
The endocannabinoids, 2-arachidonylglycerol (2-AG) and arachidonylethanolamide (AEA), have recently been shown to be selective COX-2 substrates (9,10). The products of COX-2 action on these lipids have been identified as prostaglandin glycerol esters (PG-Gs) and prostaglandin ethanolamides (PG-EAs). Investigations into the biological Enzymology. 15-HPGDH activity was determined by following the formation of NADH fluorometrically as previously described with minor modifications (16) . Briefly, reaction mixtures contained substrate (0.15 to 300 µM), 1.8 µg partially purified, human 15-HPGDH, and 1.5 mM NAD + in 1 mL of 50 mM potassium phosphate buffer (pH 7.5) containing 0.02% BSA and 1 mM EDTA. Reactions were initiated by the addition of enzyme and allowed to proceed at room temperature. NADH formed in the reaction was recorded by the increase in fluorescence at 460 nm with excitation at 340 nm. The instrument was calibrated using different concentrations of NADH determined by direct measurements of the absorbance at 340 nm, using a molar extinction coefficient of 6. Mass spectrometry. LC/MS was conducted essentially as described using a Waters 2690 Separations Module with a Zorbax RX-C18 narrow bore column (15 cm x 2.1 mm, 5 µm) interfaced to a Finnigan TSQ-7000 triple quadrupole mass spectrometer (9).
Glyceryl prostaglandins were eluted with a gradient of 10 to 40% acetonitrile in 0.001%
aqueous NaOAc in 5 min followed by isocratic elution with 40% acetonitrile.
Prostaglandin ethanolamides were eluted with a gradient of 20 to 80% acetonitrile in 0.001% aqueous NaOAc in 14 min. AGs were eluted with a gradient of 60 to 100% acetonitrile in 0.001% aqueous NaOAc in 15 min followed by isocratic elution with acetonitrile. Flow rate was fixed at 0.2 mL/min in all experiments. Quantification of glyceryl and ethanolamide prostanoids was accomplished using pentadeuterated PG-G or tetradeuterated PG-EA internal standards, respectively. Quantification of AGs was accomplished using d8-2-AG as the internal standard. Displayed mass chromatograms are normalized to a reference chromatogram defined in individual Figure legends. To assign 100% relative abundance for reference chromatograms, the area corresponding to the ion of interest was divided by the area of the deuterated internal standard employed (d4-PG-EA, d5-PG-G, or d8-2-AG as appropriate) and this ratio was considered 100%.
A similar analysis for each displayed chromatogram permits presentation of chromatograms with identical abundance scales as in the reference chromatogram. PGE 2 quantification was conducted by gas chromatography/negative ion chemical ionization mass spectrometry as previously described (18) . All displayed mass chromatograms and spectra are representative of at least three independent experiments.
Results
Plasma stability of PG-Gs, PG-EAs, and AGs. To examine the metabolic stability of PG-Gs in plasma, synthetic PGE 2 -G (4 µg/mL) was incubated in freshly obtained rat plasma at 37˚ C. As shown in Figure 1 , PGE 2 -G disappeared with a half-life of 14.4 ± 0.4 s (mean ± S.E., n = 3). Regiospecific metabolism was noted with 1(3)-PGE 2 -G disappearing more rapidly than 2-PGE 2 -G ( Fig. 2A and Eq. 2). Metabolism was inhibited by pretreating plasma with the non-specific hydrolase inhibitor, potassium fluoride (Fig.   2B ). The half-time for appearance of PGE 2 from PGE 2 -G in rat plasma was 16.0 ± 0.9 s (mean ± S.E., n = 3) which corresponds closely with the half-life of PGE 2 -G disappearance (Eq. 3). Similar experiments to probe the stability of PGE 2 -G were conducted in human plasma. In contrast to the results with rat plasma, incubation of synthetic PGE 2 -G (4 µg/mL) in freshly obtained human plasma at 37˚ C led to no detectable loss of the glyceryl prostanoid up to 10 min (Fig. 3) . When human whole blood was substituted for plasma, modest PGE 2 -G loss was observed with a half-life of approximately 7 min (Fig. 3 ).
Insert eq 2

Insert eq 3
The dramatic species differences observed in PGE 2 -G plasma stability prompted an evaluation of the stability of the parent endocannabinoid, 2-AG, and the thermodynamically more stable isomer, 1-AG, in rat and human plasma. As expected, both AGs were more rapidly metabolized in rat plasma with approximate half-lives of 0. To examine PG-EA stability in plasma, PGE 2 -EA (4 µg/mL) was incubated in both rat and human plasma. In contrast to the PG-Gs, no rapid hydrolysis of PGE 2 -EA was observed. After 5h at 37˚ C, 50% and 75% of the starting PGE 2 -EA remained in human and rat plasma, respectively ( This mass corresponds to a product of dehydration of PGE 2 -EA and a similar product was generated by base-treatment of PGE 2 -EA (Fig. 5C , Eq. 4). Base-treatment of PGE 2 is known to provide the dehydration/isomerization product, PGB 2 . The degradation product found in rat plasma treated with PGE 2 -EA, as well as base-treated PGE 2 -EA, displayed absorption maxima at 276 nm consistent with a PGB 2 -like structure ( Fig. 5D and data not shown). Assuming an extinction coefficient similar to PGB 2 (ε = 26,000 M -1 cm -1 ), more than two-thirds of the starting PGE 2 -EA was recovered from rat plasma as PGB 2 -EA after 40 h at 37˚ C. No significant PGB 2 free acid generation was observed in rat plasma incubations (data not shown). Thus, hydrolysis of PGE 2 -EA to PGE 2 does not appear to occur at a measurable rate in rat or human plasma.
Insert eq 4
CSF stability of PG-Gs and PG-EAs. To assess the stability of glyceryl and ethanolamide prostaglandins in CSF, PGE 2 -G and PGE 2 -EA (4 µg/mL) were incubated at 37 ˚ C for 5 h in freshly obtained blood-free, canine or human CSF or commercially obtained blood-free, bovine CSF. No significant degradation was observed in incubations of PGE 2 -G or PGE 2 -EA in CSF from these species (Fig. 6 ). -G could not be determined due to the extremely low activity observed with this substrate at all concentrations examined (Fig. 8) .
15-HPGDH oxidation of PG-Gs and PG-
In vivo pharmacokinetics of PGE 2 -G and PGE 2 -EA. In vivo catabolism of endocannabinoid-derived PGE 2 derivatives was investigated by injecting rats with these lipids (2 mg/kg, i.v.) and quantifying plasma concentrations over a 24 h period. No detectable starting material was evident in plasma from PGE 2 -G-treated animals at 5 min after dosing (n = 3). In contrast, PGE 2 -EA was detectable in plasma up to 2 hours after treatment. Plasma levels decreased monoexponentially with an apparent half-life of 380 ± 50 s (mean ± S.E., n = 3). The calculated t = 0 concentrations were quite low (1.1 ± 0.2 µg/mL) indicating a large apparent volume of distribution (approximately 360 mL).
Discussion
The present findings establish the metabolic stability of endocannabinoid-derived PG-like lipids in a variety of biological settings. The oxygenated 2-AG product, PGE 2 -G, proved highly labile in rat plasma (Fig. 1) . Hydrolytic metabolism was demonstrated by preferential catabolism of the less sterically hindered 1(3)-glyceryl esters when compared to the 2-glyceryl ester, sensitivity to potassium fluoride inhibition, and a half-time for PGE 2 generation essentially indistinguishable from the half-life observed for PGE 2 -G hydrolysis (Fig. 2) . In stark contrast, PGE 2 -G was stable in human plasma. The dramatic species differences observed between human and rat plasma are consistent with previous metabolism studies of non-natural PG esters (24, 25) . Although stable in human plasma, PGE 2 -G was catabolized in human whole blood with a half-life of approximately 7 min.
Enhanced ester lability in human whole blood when compared to plasma has been reported for both prostanoid and non-prostanoid esters and suggests a role for blood cells in glyceryl PG metabolism in humans (25) (26) (27) (28) (29) (30) (31) .
Marked species differences in plasma PGE 2 -G stability suggested that the parent endocannabinoid also might be metabolized differently in rat and human plasma. As seen in Figure 4 , 2-AG and 1-AG were significantly more stable in human plasma than in rat plasma. The demonstrated lability of AGs in rat plasma is consistent with previous findings indicating that 2-AG is rapidly hydrolyzed in mouse whole blood (32) . Taken together, these results suggest that rodent models may not be wholly adequate for investigating the human biology of glycerol esters of both PGs and arachidonic acid and highlight possible complications in AG and PG-G quantification from rodent tissue (e.g.
blood contamination).
In contrast to esterified PGs, PGE 2 -EA was slowly metabolized in plasma from both rats and humans. Plasma slowly promotes the dehydration/isomerization of PGE 2 -EA to provide PGB 2 -EA. The more rapid degradation of PGE 2 -EA in human plasma is consistent with earlier demonstrations that human albumin promotes the conversion of PGE 2 to PGB 2 more efficiently than rat albumin (33) . However, in contrast to glycerol esters, this species difference was very minor and unlikely to affect the overall in vivo disposition of PGE 2 -EA, suggesting that rodents may serve as adequate models for investigating the human biology of PG-EAs. This conclusion is supported by recent evidence that the cardiovascular effects of exogenous AEA, but not 2-AG, are mediated by cannabinoid receptors and not through arachidonic acid or subsequent metabolites in anesthetized mice (32) .
The demonstrated stability of PGE 2 -G and PGE 2 -EA in the CSF of three mammalian species indicates that this biological fluid has no significant metabolic capacity for neutral PG derivatives. This finding suggests that in vivo detection and quantification of endocannabinoid-derived PGs may be possible by careful sampling of CSF. Rigorous exclusion of blood and the use of higher sensitivity detection methods will be required to test this possibility and several approaches are currently under evaluation. High sensitivity PG detection methods typically rely on immunological techniques, which are unlikely to distinguish PG free acids from PG-Gs or PG-EAs. Thus, the simple transfer of available PG detection technologies will most likely not prove useful.
The cytosolic, NAD + -dependent 15-HPGDH is the key enzyme in PG inactivation in vivo. In fact, resistance to 15-HPGDH oxidation has been used as a rational drug design strategy in the development of long-lasting, non-natural prostaglandin analogues (e.g. misoprostol). The demonstration that both PGE 2 -G and PGE 2 -EA are oxidized by 15-HPGDH confirms that carboxylic acid-enyzme interactions are not critical for turnover.
Despite the tolerance for uncharged moieties at carbon 1, a stepwise increase in K m was observed with increasing steric bulk at the carboxylate. As determined by 1 H NMR and as illustrated in Figure 2 , the tested synthetic PGE 2 -G is a 9:1 mixture of 1(3)-PGE 2 -G and 2-PGE 2 -G (data not shown). Our results suggest that the sterically more hindered 2-PGE 2 -G, the expected initial product of 2-AG oxygenation by COX-2, would be an even worse 15-HPGDH substrate than the PGE 2 -G employed in these studies. More importantly, the decreased activity of 15-HPGDH toward PG-Gs and PG-EAs suggests that these lipids may be longer lasting in vivo than the PGs. This raises the possibility that COX-2-generated PG esters or amides exert biological actions in tissues remote from their site of generation thereby extending the range of action of this class of eicosanoids.
A rigorous test of the hypothesis that endocannabinoid-derived PGs may be metabolically more stable than their free acid counterparts was conducted using a rat model. Thirty years ago, Hamberg and Samuelsson demonstrated that, in humans, intravenously administered PGE 2 was rapidly cleared from blood with essentially no parent PG remaining after just 4.5 min (34) . The importance of 15-HPGDH in PGE 2 clearance was supported by the identification of the primary metabolite as a 15-keto-derivative.
Although 15-HPGDH is expressed throughout the body, tissues with the highest levels of activity include lung and kidney (35) . Consequently, pulmonary and renal blood flow are critical determinants of rapid PG inactivation in vivo. The enhanced renal and pulmonary blood flow in rats compared to humans predisposes to rapid PG clearance.
In rats, PGE 2 -G was rapidly cleared after intravenous administration with no detectable parent compound present in plasma at 5 min. The rapid catabolism of PGE 2 -G is consistent with the hydrolytic lability of the glycerol moiety in rat plasma. Given the hydrolytic stability of PGE 2 -G in human plasma, further investigations on the metabolism of glyceryl PGs in species with less active plasma esterases should prove informative. In contrast to the glycerol ester, PGE 2 -EA was detectable in rat plasma up to 2 h after dosing suggesting that this AEA-derived prostanoid is significantly longer lasting than PGE 2 . In addition, a half-life greater than 5 min theoretically permits significant blood transport prior to inactivation. Conceivably, locally produced COX-2 metabolites of AEA could act on a distant target organ equipped with an appropriate PG-EA receptor or amidase.
These findings provide the first insights into the catabolism of COX-2-generated, oxygenated endocannabinoid products. The dramatic species differences observed with glycerol esters indicate that the rat is not a suitable model for studying the in vivo human biology of 2-AG and PG-Gs. Less efficient 15-hydroxyl oxidation by 15-HPGDH suggests that COX-2 metabolites of 2-AG and AEA may be significantly more stable than the corresponding arachidonic acid metabolites (PGs). This is supported by the observed in vivo pharmacokinetics of PGE 2 -EA. The rapid metabolism of PGE 2 -G in rat does not preclude an extended lifespan for this ester in humans particularly considering the marked differences in plasma esterase activity between the two species. Taken together, the present findings support the possibility that endocannabinoid-derived PGlike compounds may be sufficiently stable in humans to exert actions systemically either as PG precursors or as unique signal mediators. 
